RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.

Kazuhiko NakagawaEdward B GaronLing GaoSophie CalliesAnnamaria ZimmermannRichard WalgrenCarla Visseren-GrulMartin Reck
Published in: Cancer chemotherapy and pharmacology (2022)
ClinicalTrials.gov, NCT02411448.